CPT group (n=66) | DMARD contrast group (n=181) | ||||||
---|---|---|---|---|---|---|---|
Before | After | ES | ES | Before | After | ||
ESR1-151 (mm/1st h) | 68 (33) | 38 (27) | 1.011-220 | 0.601-220 | 41 (28) | 26 (24) | |
CRP1-151(mg/l) | 57 (46) | 16 (32) | 1.051-220 | 0.751-220 | 34 (42) | 11 (18) | |
Haemoglobin (mmol/l) | 7.5 (1.0) | 7.6 (1.0) | 0.09 | 0.311-168 | 7.9 (0.9) | 8.2 (0.9) | |
Platelets (×109/l) | 358 (128) | 353 (125) | 0.04 | 0.451-220 | 344 (120) | 292 (103) | |
EMS1-151(min) | 126 (110) | 34 (43) | 1.171-220 | 0.541-220 | 111 (153) | 44 (94) | |
Joint score1-151 (0–534) | 355 (137) | 244 (144) | 0.801-220 | 1.011-220 | 142 (100) | 52 (79) | |
Grip strength1-151 (kPa) | 8 (11) | 15 (14) | 0.561-220 | 0.401-220 | 30 (22) | 40 (25) | |
IRGL scales: | |||||||
Mobility (7–28) | 12.1 (3.5) | 13.4 (4.0) | 0.351-150 | 0.451-220 | 17.8 (6.2) | 20.6 (6.0) | |
Self care (8–32) | 14.9 (5.2) | 17.8 (5.5) | 0.551-168 | 0.511-220 | 22.6 (6.2) | 25.7 (6.1) | |
Pain (6–25) | 22.0 (3.0) | 12.8 (5.3) | 2.221-220 | 1.071-220 | 18.5 (4.6) | 13.2 (5.4) | |
Depressed mood (0–24) | 5.9 (5.2) | 2.2 (4.1) | 0.771-220 | 0.461-220 | 5.3 (4.9) | 3.3 (3.6) | |
Cheerful mood (0–24) | 7.9 (4.2) | 11.8 (3.5) | 0.991-220 | 0.501-220 | 9.6 (4.6) | 11.9 (4.3) | |
Anxiety (10–40) | 21.9 (5.0) | 19.2 (4.9) | 0.541-220 | 0.381-220 | 20.4 (6.3) | 18.1 (5.9) | |
Potential support (5–20) | 16.2 (4.1) | 15.8 (4.2) | 0.10 | 0.11 | 16.8 (3.6) | 16.4 (3.7) | |
Actual support (3–12) | 6.5 (1.7) | 6.5 (1.9) | 0.00 | 0.04 | 6.6 (1.8) | 6.5 (1.8) | |
Impact on eating/sleeping (2–8) | 4.3 (1.3) | 3.8 (1.2) | 0.441-165 | 0.461-220 | 4.2 (1.6) | 3.5 (1.5) | |
Impact on relationships (2–8) | 3.4 (1.8) | 3.2 (1.6) | 0.09 | 0.08 | 3.1 (1.6) | 3.3 (1.8) |
↵1-151 ESR = erythrocyte sedimentation rate, Westergren method, range 0–140; CRP = C reactive protein, range 0–∞; EMS = early morning stiffness; joint score = according to Thompson; grip strength = with Martin vigorimeter.
↵1-152 Second assessment (denoted “after” in the heading of the table) at 1.3 (SD 1.0) weeks for the CPT group and 12 months in the DMARD contrast group.
↵1-154 Statistical significance levels of changes from baseline:
↵1-150 p<0.05;
1-160 p<0.01;
↵1-165 p<0.001;
↵1-168 p<0.0001;
↵1-220 p<0.00001; all statistically significant changes denote improvement.